2.4 min readPublished On: April 21st, 2021By News Team
OAKLAND – Cannabis has become a popular alternative treatment for several different illnesses and ailments. Cannabidiol (CBD), a non-psychoactive cannabinoid, in particular is gaining attention for its plethora of health benefits.
CBD does not get its users “high” – it is used completely for medical purposes. People are using CBD for everything from autism to arthritis – but how does the body process CBD exactly? The answer is the endocannabinoid system.
What is the endocannabinoid system?
The human body processes cannabinoids like CBD and THC (the psychoactive cannabinoid) through the CB1 and CB2 receptors in the brain. These receptors then send signals throughout the body and activates the health benefits of the cannabinoid. Not everyone knows about the endocannabinoid system but as cannabis becomes a more popular medicine, the research will grow. Here are five things you may not know about the body’s endocannabinoid system:
The endocannabinoid system was not discovered until 1988. THC was first isolated in the 1960s in Israel, but it wasn’t until the late 1980s that the first cannabinoid receptor was discovered in the brain of a rat. Scientists later used a synthetic version of THC to mapping CB receptors.
The endocannabinoid system helps to regulate brain activity. Brain cells (neurons) communicate by sending electrochemical signals to each other. Each neuron must listen to its partners to decide whether it will fire off its own signal at any given moment. Endocannabinoids allow receiver neurons to regulate how much input they’re getting, and they do this by sending retrograde signals (endocannabinoids) back to overactive sender neurons.
Endocannabinoids have anti-inflammatory properties. Researchers have found that endocannabinoids are produced in the body when the immune system is activated and support the anti-inflammatory process. CBD has shown the most efficacy as an anti-inflammatory so far but other cannabinoids such as CBG are also being looked at.
Endocannabinoid receptors are located all throughout the body. Many people believe that the brain is the only place in the body where cannabinoids are processed – however, there are actually receptors throughout. They are in muscles, connective tissue, organs, and immune cells in addition to the brain. These receptors may target different areas but all exist to maintain homeostasis.
The endocannabinoid system promotes prosocial behavior. Researchers have found that the endocannabinoid system could promote exploratory and social behaviors, and may regulate our brain’s response to over-stimulating experiences.
The body has many important systems in place to ensure optimal health and function and the endocannabinoid system is just as critical as anything else. As more research is conducted on the topic, it is almost certain that the role of the endocannabinoid system will be found to be even more complex and powerful than once thought.
Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.
MONTREAL - Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a producer of premium-grade cannabis and derivative products with two mega cultivation facilities based in Québec spanning over 1,650,000 sq. ft., today announced its ...
DÜSSELDORF, Germany and TEL AVIV, Israel - Panaxia Labs Israel Ltd. (TASE: PNAX), a global pharma company that develops, manufactures and markets advanced medical cannabis-based products in pharmaceutical quality, and Neuraxpharm, Europe's pharma company in ...
SAN FRANCISCO Study results indicate the potential of Cannabis-Responsive biomarkers as a powerful tool in quantifying, at the metabolic level, the benefits of successful medical cannabis treatment in children with ASD. Study results also show the potential ...
DISCLAIMER NOTE: This email should be considered strictly private and confidential. Sender of this email is not a United States Securities Dealer, nor Broker, nor U.S. Investment Adviser. Sender is a Registered Corporation and Consultant, and makes no warranties, nor representations as to the buyer, seller, or transaction. Furthermore, this email includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Read more